ENXTPA:DBV

Stock Analysis Report

Executive Summary

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has DBV Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DBV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

DBV

6.7%

FR Biotechs

7.1%

FR Market


1 Year Return

-45.6%

DBV

-35.6%

FR Biotechs

-17.6%

FR Market

Return vs Industry: DBV underperformed the French Biotechs industry which returned -35.3% over the past year.

Return vs Market: DBV underperformed the French Market which returned -12.9% over the past year.


Shareholder returns

DBVIndustryMarket
7 Day-8.5%6.7%7.1%
30 Day-59.6%-29.5%-22.3%
90 Day-61.8%-30.6%-25.9%
1 Year-45.6%-45.6%-35.5%-35.6%-14.8%-17.6%
3 Year-88.8%-88.8%-68.5%-68.5%0.07%-9.2%
5 Year-83.0%-83.0%-70.6%-70.8%9.7%-5.9%

Price Volatility Vs. Market

How volatile is DBV Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DBV Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DBV (€7.33) is trading below our estimate of fair value (€28.21)

Significantly Below Fair Value: DBV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DBV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DBV is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DBV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DBV is good value based on its PB Ratio (2x) compared to the FR Biotechs industry average (2x).


Next Steps

Future Growth

How is DBV Technologies forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

53.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DBV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.1%).

Earnings vs Market: DBV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DBV's is expected to become profitable in the next 3 years.

Revenue vs Market: DBV's revenue (50.3% per year) is forecast to grow faster than the French market (3.8% per year).

High Growth Revenue: DBV's revenue (50.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DBV is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has DBV Technologies performed over the past 5 years?

-29.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DBV is currently unprofitable.

Growing Profit Margin: DBV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DBV is unprofitable, and losses have increased over the past 5 years at a rate of -29.5% per year.

Accelerating Growth: Unable to compare DBV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DBV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: DBV has a negative Return on Equity (-89.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is DBV Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DBV's short term assets (€182.1M) exceed its short term liabilities (€48.1M).

Long Term Liabilities: DBV's short term assets (€182.1M) exceed its long term liabilities (€21.8M).


Debt to Equity History and Analysis

Debt Level: DBV's debt to equity ratio (0.8%) is considered satisfactory.

Reducing Debt: DBV's debt to equity ratio has reduced from 3.6% to 0.8% over the past 5 years.


Balance Sheet

Inventory Level: DBV has a low level of unsold assets or inventory.

Debt Coverage by Assets: DBV's debt is covered by short term assets (assets are 140.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DBV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DBV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35.3% each year


Next Steps

Dividend

What is DBV Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DBV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DBV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DBV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DBV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DBV's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Daniel Tassé (59yo)

1.33s

Tenure

€2,772,270

Compensation

Mr. Daniel Tassé has been the Chief Executive Officer at DBV Technologies S.A. since November 29, 2018 and has been its Director since March 5, 2019. He served as the Chairman and Chief Executive Officer o ...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD4.57M) is above average for companies of similar size in the French market ($USD613.82K).

Compensation vs Earnings: Insufficient data to compare Daniel's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director1.33yrs€2.77mno data
Pierre-Henri Benhamou
Co-Founder & Member of Scientific Advisory Board1yr€26.20kno data
Laurent Martin
Deputy Chief Executive Officer4.75yrs€189.79k0.16% 658.4k
Ramzi Benamar
Chief Financial Officer0.17yrno datano data
Hugh Sampson
Chief Scientific Officer & Member of Scientific Advisory Board7.83yrsno datano data
Sara Sherman
Senior Director of Investor Relations & Strategyno datano datano data
Joseph Becker
Vice President of Global Corporate Communicationsno datano datano data
Caroline Daniere
Chief Human Resources Officer1.17yrsno datano data
Wence Agbotounou
Chief Clinical Trial Officer & Senior VP3.83yrsno datano data
Lucie Mondoulet
Senior VP & Deputy CSO3.83yrsno datano data

3.8yrs

Average Tenure

61.5yo

Average Age

Experienced Management: DBV's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director1.33yrs€2.77mno data
Pierre-Henri Benhamou
Co-Founder & Member of Scientific Advisory Board1yr€26.20kno data
Hugh Sampson
Chief Scientific Officer & Member of Scientific Advisory Board7.83yrsno datano data
Claire Giraut
Independent Director3.75yrs€90.00kno data
Michel de Rosen
Non-Executive Chairman1yr€141.90k0.043% 172.1k
Torbjørn Bjerke
Independent Director14.17yrs€87.00k0.065% 262.3k
Paul-Henri Lambert
Member of the Scientific Advisory Boardno datano datano data
Christophe Dupont
Chairman of the Scientific Advisory Boardno datano datano data
Gideon Lack
Member of the Scientific Advisory Boardno datano datano data
Robert Zeiger
Member of the Scientific Advisory Board0.83yrno datano data

1.0yrs

Average Tenure

64yo

Average Age

Experienced Board: DBV's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.


Top Shareholders

Company Information

DBV Technologies S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DBV Technologies S.A.
  • Ticker: DBV
  • Exchange: ENXTPA
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €400.779m
  • Shares outstanding: 54.86m
  • Website: https://www.dbv-technologies.com

Number of Employees


Location

  • DBV Technologies S.A.
  • 177-181 avenue Pierre Brossolette
  • Montrouge
  • Ile-de-France
  • 92120
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DBVENXTPA (Euronext Paris)YesCommon StockFREURMar 2012
DBVDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2012
0QAJLSE (London Stock Exchange)YesCommon StockGBEURMar 2012
DBVPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURMar 2012
DBVT.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2012
DBVTNasdaqGS (Nasdaq Global Select)SPON ADR EACH REPR ORDUSUSDOct 2014
DBVADB (Deutsche Boerse AG)SPON ADR EACH REPR ORDDEEUROct 2014

Biography

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 22:55
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.